Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

XNCR vs XENE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XNCR Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 5–5 Matrix Metrics)

XNCR Overall Winner 6-Pillar Tally: XNCR 5 – 1 XENE Matrix Metrics: XNCR 5 – 5 XENE

As of Nov 16, 2026, Xencor, Inc. (XNCR) is the stronger overall head-to-head candidate over Xenon Pharmaceuticals Inc (XENE) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). XNCR carries a Unified Composite Score of 29.6/100 (SELL) at $35.61 (68.0x Forward P/E, -72.7% operating margin), whereas XENE carries 33.3/100 (SELL) at $39.30 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While XENE currently prints a higher short-term Unified Composite Score (33.3/100 SELL vs. XNCR 29.6/100 SELL), XNCR captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-72.7% vs. 0.0% operating margin) and revenue trajectory (+454.9% vs. -100.0% YoY).
  • Defensive Composite Rating Caution: Although XNCR compares more favorably head-to-head, both XNCR (29.6/100 SELL) and XENE (33.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: XNCR trades in a Markup technical trend (BREAKOUT options phase, RSI 62.5); meanwhile XENE is in a Breakdown options structure phase (RSI 51.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About XNCR vs XENE
XNCR NASDAQ Head-to-Head Winner
Xencor, Inc.
Pharmaceutical Preparations
$35.61
-3.99% 1D
Market Cap $2.9B
TTM Revenue $200M
Forward P/E 68.0x
Beta / 30D Vol 1.21β · 87% Vol
Unified Composite Score
29.6 / 100 SELL
Tech 50.0 Fund 32.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (9.7% over 20 days), RSI 62
RSI-14: 62.5 · SMA20: $32.16 · SMA50: $27.52
XENE NASDAQ
Xenon Pharmaceuticals Inc
Pharmaceutical Preparations
$39.30
-2.9% 1D
Market Cap $4.0B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.70β · 36% Vol
Unified Composite Score
33.3 / 100 SELL
Tech 15.0 Fund 44.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 51.2 · SMA20: $38.20 · SMA50: $40.73

6-Pillar Scorecard Institutional Category Breakdown (XNCR 5 – 1 XENE)

Columns: Metric · XNCR · XENE
1. Valuation Multiples XNCR
Forward P/E 68.0x N/M
Trailing P/E 68.0x N/M
PEG Ratio N/M N/M
EV / Revenue 14.8x N/M
2. Growth & Scale XNCR
Revenue Growth (YoY) +454.9% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $200M N/A
Market Cap $2.9B $4.0B
3. Profitability & Quality XENE
Gross Margin -42.5% N/A
Operating Margin -72.7% 0.0%
Net Profit Margin -58.8% 0.0%
Return on Equity (ROE) -19.9% -50.3%
4. Balance Sheet & Cash Flow XNCR
Cash Generation (TTM) -$176M -$357M
Cash Flow Margin -88.0% N/A
Net Cash / Leverage $101M Net Debt (0.29x D/E) $77M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning XNCR
Options Structure Phase BREAKOUT BREAKDOWN
Current IV / %ile 79.0% (10th %ile) 57.6% (14th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat XNCR
OpEx & R&D Intensity 30.2% of Rev ($61M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: XNCR (5) vs XENE (5)
Institutional Metric XNCR XENE Criterion Row Edge
Market Capitalization
Scale
$2.9B $4.0B Larger Scale XENE
Trailing P/E Ratio
Valuation
68.0x N/M Lower Multiple XNCR
Forward P/E Ratio
Valuation
68.0x N/M Lower Multiple XNCR
Revenue Growth (YoY)
Growth
+454.9% -100.0% Higher Growth XNCR
Operating Margin (TTM)
Profitability
-72.7% 0.0% Higher Margin XENE
Net Profit Margin
Profitability
-58.8% 0.0% Higher Margin XENE
Return on Equity (ROE)
Capital Efficiency
-19.9% -50.3% Higher ROE XNCR
52-Week Range Position
Momentum
84% ($10–$41) 15% ($33–$73) Stronger Trend XNCR
Beta / 30D Volatility
Risk Regime
1.21β · 87% Vol 0.70β · 36% Vol Lower Realized Risk XENE
Unified Institutional Score
Composite Signal
29.6 / 100 (SELL) 33.3 / 100 (SELL) Higher Composite XENE
Trailing 12M Revenue (USD)
Operating Scale
$200M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-42.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 14.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$176M ($101M Net Debt (0.29x D/E)) -$357M ($77M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon XNCR +38.48 pp
XNCR: +55.84% · XENE: +17.36%
3M Horizon XNCR +77.93 pp
XNCR: +40.14% · XENE: -37.79%
6M Horizon XNCR +248.79 pp
XNCR: +221.97% · XENE: -26.82%
1Y Horizon XNCR +156.38 pp
XNCR: +154.54% · XENE: -1.84%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period XNCR Revenue XENE Revenue XNCR Op. Margin XENE Op. Margin Margin Leader
FY2018 $40M N/A -195.5% N/A XNCR
FY2019 $160M $10M 8.8% -627.0% XNCR
FY2020 $120M $30M -62.6% -97.3% XNCR
FY2021 $280M $20M 15.9% -428.4% XNCR
FY2022 $160M $10M -50.1% -1368.9% XNCR
FY2023 $170M N/A -75.8% N/A XNCR
FY2024 $110M N/A -161.5% N/A XNCR
FY2025 $130M $10M -141.4% -4974.3% XNCR

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
XNCR BREAKOUT
58d in phase · OBV ACCUMULATION
Current IV 79.0%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact XNCR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
XENE BREAKDOWN
175d in phase · OBV ACCUMULATION
Current IV 57.6%
IV Percentile 14th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact XENE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
XNCR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.9B market capitalization and -72.7% operating margin.
OpEx & R&D Reinvestment 30.2% of Rev ($61M)
90D Engineering Disclosures 0 Published
XENE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.0B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ XNCR vs XENE Key Questions & Quantitative Answers

As of Nov 16, 2026, Xencor, Inc. (XNCR) is the stronger overall head-to-head candidate over Xenon Pharmaceuticals Inc (XENE) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). XNCR carries a Unified Composite Score of 29.6/100 (SELL) at $35.61 (68.0x Forward P/E, -72.7% operating margin), whereas XENE carries 33.3/100 (SELL) at $39.30 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While XENE currently prints a higher short-term Unified Composite Score (33.3/100 SELL vs. XNCR 29.6/100 SELL), XNCR captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-72.7% vs. 0.0% operating margin) and revenue trajectory (+454.9% vs. -100.0% YoY). Defensive Composite Rating Caution: Although XNCR compares more favorably head-to-head, both XNCR (29.6/100 SELL) and XENE (33.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: XNCR trades in a Markup technical trend (BREAKOUT options phase, RSI 62.5); meanwhile XENE is in a Breakdown options structure phase (RSI 51.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

XNCR leads the Growth & Scale pillar: XNCR posts +454.9% YoY revenue growth and +0.0% YoY earnings growth on $200M TTM revenue (-42.5% gross margin, -72.7% operating margin), compared with XENE at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), XNCR cumulative revenue shifted +225.0% while XENE shifted +0.0%. In operating R&D and SG&A reinvestment, XNCR deploys 30.2% of Rev ($61M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XENE.

XNCR screens cheaper on headline valuation multiples. XNCR trades at 68.0x Forward P/E, 68.0x Trailing P/E, N/M PEG, and 14.8x EV/Revenue (-88.0% FCF margin), whereas XENE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XNCR (-19.9% ROE) versus XENE (-50.3% ROE) capital efficiency.

In options market volatility and institutional positioning, XNCR carries 79.0% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.21β · 87% Vol realized risk). By comparison, XENE carries 57.6% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.70β · 36% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.